Hemiplegic Migraine and MUMS

Posted on June 15 2025, By: Cerebral Torque

Stay in the Loop on the Latest in Migraine:

Hemiplegic Migraine & MUMS

Understanding these rare but serious forms of migraine with motor weakness

Updated March 2026

What is the Motor Migraine Subtype?

Motor migraines are a clinically important group of migraine disorders characterized by unilateral weakness during attacks. Two distinct conditions fall under this umbrella: hemiplegic migraine and MUMS (Migraine with Unilateral Motor Symptoms). While both involve motor weakness, they have fundamentally different underlying mechanisms and require different approaches to diagnosis and treatment.

Hemiplegic migraine is a rare but distinct form of migraine characterized by an aura that includes true unilateral weakness along with other neurological symptoms. Unlike typical migraine, the defining feature is temporary paralysis or weakness on one side of the body during attacks, caused by underlying genetic ion channel dysfunction.

MUMS is a recently characterized migraine syndrome that presents with sensory weakness rather than true motor weakness. First systematically described in 2007, MUMS challenges traditional migraine classification by presenting with weakness that mimics stroke but constitutes a distinct migraine subtype with its own characteristic features. Importantly, MUMS is likely far more common than recognized - many headache specialists believe that a significant proportion of patients currently diagnosed with hemiplegic migraine actually have MUMS.

Both conditions affect young to middle-aged adults, can mimic stroke, and require specialized management approaches. Understanding the differences between these conditions matters not just for diagnostic accuracy, but because treatment options - particularly the use of triptans and DHE - differ meaningfully between them.

0.01%

Population Prevalence

Hemiplegic migraine affects approximately 1 in 10,000 people, making it one of the rarest migraine subtypes.

12-17

Average Age of Onset

Symptoms typically begin in adolescence, though onset can range from age 1 to 51 years.

2.5:1

Female to Male Ratio

Like other migraine types, hemiplegic migraine affects women more frequently than men.

Understanding MUMS (Migraine with Unilateral Motor Symptoms)

While MUMS is not yet formally recognized in the ICHD-3 classification system, it has significant clinical implications due to high rates of stroke misdiagnosis and substantial disability burden. This is similar to vestibular migraine, which is also not formally in the ICHD-3 but is widely accepted as a real, distinct clinical entity. As the condition gains more recognition, formal classification is likely to follow.

Sensory Weakness vs. Motor Weakness: The Key Distinction

The most important distinction between MUMS and hemiplegic migraine comes down to the type of weakness - and it's worth being precise about terminology here. The term "true weakness" is sometimes used to describe motor weakness, but this framing is problematic because sensory weakness is also a real, genuine experience for the patient. A more accurate distinction is:

Motor weakness (hemiplegic migraine): Consistent reduced strength throughout testing. The patient has trouble pushing back against resistance. Weakness follows neuroanatomical patterns and correlates with functional impairment. Gradual fatigue on repeated testing.
Sensory weakness (MUMS): Initially normal power followed by sudden loss of resistance when the examiner applies pressure. Sometimes described as "giveaway weakness." Often related to proprioceptive dysfunction - the patient doesn't fully know where their limb is in space, making coordinated resistance difficult.

Clinical significance: This pattern indicates a distinct migraine subtype with different pathophysiology, which changes both the diagnostic approach and treatment options - particularly around triptans and DHE, which can be used in MUMS but are traditionally avoided in hemiplegic migraine.

MUMS Clinical Characteristics

MUMS affects patients in their mid-30s on average (range 14-59 years) and shows a clear female predominance. The condition demonstrates several key features that distinguish it from hemiplegic migraine:

100%

Sensory Weakness

All MUMS patients demonstrate this functional weakness pattern on examination

58%

Persistent Weakness

Experience weakness between attacks, more common in chronic migraine patients

38%

Stroke Misdiagnosis

Initially told they had a stroke despite normal imaging

MUMS vs Hemiplegic Migraine: Key Differences

MUMS Features

Weakness pattern: Sensory/giveaway weakness
Aura progression: "Avalanche" or "tsunami" - multiple symptoms simultaneously
Age of onset: Mid-30s average
Genetics: No known genetic basis
Imaging: Always normal
Recovery: Often incomplete between attacks
Associated features: High rates of chronic migraine
Triptans/DHE: Can be used

Hemiplegic Migraine Features

Weakness pattern: Motor weakness
Aura progression: Ordered, mappable march across brain regions
Age of onset: Often childhood/adolescence
Genetics: Known ion channel mutations
Imaging: May show transient changes
Recovery: Usually complete between attacks
Associated features: May have cerebellar signs
Triptans/DHE: Traditionally avoided

Clinical Recognition of MUMS

MUMS should be suspected when patients present with:

Subjective arm weakness with objective arm AND leg involvement on exam
Sensory/giveaway weakness pattern on examination
Normal brain imaging despite concerning symptoms
High healthcare utilization with repeated stroke workups
"Avalanche" or "tsunami" symptom onset rather than orderly progression
Symptoms that can occur without headache pain
Aura pattern that doesn't map cleanly onto a single anatomical pathway

Why MUMS is Called "Super Migraine"

MUMS has earned the colloquial term "super migraine" for several reasons:

Symptom intensity: More severe light sensitivity, nausea, and scalp sensitivity than typical migraine
Additional features: More frequent eyelid drooping, eye redness, and tearing on the headache side
Duration: Symptoms can last from minutes to months, far exceeding typical aura duration
Complexity: Multiple neurological symptoms occurring simultaneously rather than in sequence
Association with chronic migraine: Often occurs in patients with high-frequency migraine patterns

Historical Development of MUMS Understanding

Original research (Dr. William Young, 2007): Study of 24 patients with normal MRIs during severe migraine attacks who developed unilateral weakness. All patients shared similar patterns distinct from traditional hemiplegic migraine.

Key methodology: Compared patients with MUMS to those with equally severe migraine without motor symptoms to identify distinguishing features.

Major findings: MUMS patients had more severe light sensitivity, nausea, scalp sensitivity, eyelid drooping, eye redness, and tearing - essentially "super migraine" characteristics.

Clinical impact: Recognition that many neurological symptoms accompanying migraine may not fit traditional aura definitions but constitute important migraine subtypes requiring different treatment approaches. As more headache specialists become familiar with MUMS, it is increasingly clear that it may be far more prevalent than hemiplegic migraine - the challenge is that it simply isn't in the ICHD criteria yet, so it often gets lumped into the hemiplegic migraine category by default.

Understanding Aura and Brain Mechanisms

To understand motor migraines, it's essential to grasp what happens in the brain during aura. The traditional view that aura is caused by blood vessel constriction followed by dilation has been largely replaced by our understanding of cortical spreading depression. Even in medical education, the vascular theory was being taught as fact not long ago - progress in understanding migraine pathophysiology has moved fast, but teaching hasn't always kept up.

Cortical Spreading Depression Explained

What it is: A slow-moving electrical wave that travels across the brain's surface, causing temporary loss of normal brain activity followed by recovery.

How it manifests: Creates the classic "marching" pattern of aura symptoms as the wave moves through different brain regions - visual cortex first (causing visual aura), then sensory cortex (numbness/tingling), then motor cortex (weakness).

Time course: The wave moves slowly, which explains why aura symptoms develop gradually over 5-60 minutes rather than appearing suddenly like stroke symptoms.

Historical note: The Brazilian physiologist Leão was among the first to document this slow-spreading depolarizing electrical activity, and the phenomenon has since been reproduced in animal models and correlated with migraine preventive medications that reduce the likelihood of triggering these waves.

Visual Aura Patterns

Classic visual auras include the "scintillating scotoma" or "fortification spectrum" - characterized by shimmering zigzag lines that start small near the center of vision and expand outward over 10-30 minutes.

Less Common Aura Types

Alice in Wonderland syndrome: Distorted perception where objects appear closer/farther than they are, or feeling that one's own body is misshapen
Olfactory auras: Unusual smells that aren't actually present
Gustatory auras: Strange tastes
Déjà vu/jamais vu: Feelings of familiarity or unfamiliarity
Delirium-like states: Brief periods of confusion or altered consciousness
Cognitive/dysphasic auras: Brain fog, word-finding difficulties, and speech disruption that come and go - often misattributed to other causes

Many patients don't realize that these non-visual aura symptoms are actually quite common. When people present with episodic cognitive fog, tingling, or transient speech difficulties, a thorough migraine history is always worth taking.

Late-Life Migraine Accompaniments

Some patients, particularly older adults, experience aura-like symptoms without significant headache. These "migraine equivalents" can be confused with stroke and often prompt emergency room visits. They feature:

Visual or sensory symptoms that spread like typical aura
Episodes lasting 15-20 minutes each
Tendency to cluster over days or weeks, then disappear for months
Little to no headache pain
Normal brain imaging and stroke workup

Migraine and Functional Neurological Disorder (FND): An Overlap Worth Knowing

Both migraine and functional neurological disorder (FND) involve neurological symptoms that don't always correlate with conventional imaging or objective testing. This overlap can create diagnostic challenges - particularly with conditions like MUMS, where sensory weakness may superficially resemble FND presentations.

The key point is that these are not mutually exclusive diagnoses, and both are real. Migraine is one of the best-characterized examples of how the brain can generate dramatic, disabling neurological symptoms without structural damage on MRI. When a patient doesn't fit a clean textbook picture, it's worth considering whether migraine, FND, or both may be contributing - and treating accordingly. A trial of migraine preventive therapy is often a reasonable first step when the picture is unclear.

Hemiplegic Migraine: Types and Genetics

Hemiplegic migraine is classified into familial and sporadic forms, with the familial type further subdivided based on genetic mutations. Understanding these genetic foundations helps guide diagnosis and treatment decisions - and is one area where truly targeted, mechanism-based therapy is already possible.

Familial Hemiplegic Migraine Type 1 (FHM1)

Gene: CACNA1A (chromosome 19p13)

Function: Encodes alpha-1A subunit of P/Q-type calcium channel

Penetrance: 67-89%

Clinical features: Approximately 50% have cerebellar involvement (gaze-evoked nystagmus, ataxia, vermian atrophy). Some families have severe attacks with coma and prolonged hemiplegia.

Associated conditions: Spinocerebellar ataxia type 6, episodic ataxia type 2, benign paroxysmal torticollis of infancy

Special consideration: S218L variant associated with severe phenotype - mild head trauma can trigger attacks with prolonged hemiplegia, coma, cerebral edema, or death

Familial Hemiplegic Migraine Type 2 (FHM2)

Gene: ATP1A2 (chromosome 1q23)

Function: Encodes catalytic subunit of sodium/potassium ATPase

Penetrance: 63-87%

Clinical features: Less well-defined than FHM1, but different variants linked to frequent long-lasting hemiplegia, recurrent coma, or seizures with intellectual disability. Some have cerebellar involvement.

Associated conditions: Migraine with brainstem aura, various epilepsy syndromes, rarely alternating hemiplegia of childhood

Genetic overlap: Some ATP1A2 variants cause both FHM2 and alternating hemiplegia of childhood

Familial Hemiplegic Migraine Type 3 (FHM3)

Gene: SCN1A (chromosome 2q24)

Function: Encodes transmembrane alpha subunit of brain sodium channel

Penetrance: 100%

Clinical features: Only a few families reported. Phenotype includes epilepsy. Novel feature: "elicited repetitive daily blindness" - stereotyped spells of blindness (usually bilateral) lasting up to 30 seconds, triggered by eye rubbing, light changes, or standing.

Associated conditions: Multiple epilepsy syndromes, febrile seizures

Unique feature: Visual symptoms can be triggered by specific actions, distinguishing it from other FHM types

Hemiplegic Migraine and Epilepsy

Epilepsy and migraine are separate conditions, but they are more likely to co-occur than chance would predict. This comorbidity is especially relevant in hemiplegic migraine - particularly FHM2 and FHM3 - where seizures have been reported as part of the clinical picture in some families.

Historically, the two conditions were sometimes conflated; some of the anti-seizure medications we use for migraine prevention are a legacy of that overlap. We now understand that cortical spreading depression (a surface-level depolarizing wave) and epileptic seizure activity (deeper, more rapid electrical discharge) are distinct processes, even if they share some mechanisms. For patients who have both conditions, the important takeaway is that having them together doesn't mean something more ominous is happening - it simply means both need to be addressed.

Emerging Genetic Findings

Recent research has identified PRRT2 variants in 17% of hemiplegic migraine patients who don't have mutations in the three established genes. While not an ion channel gene, PRRT2 encodes a protein that interacts with SNAP25, which may regulate voltage-gated calcium channels.

Sporadic Hemiplegic Migraine

Patients who are the first in their family to develop hemiplegic migraine have sporadic hemiplegic migraine. However, up to 20% of sporadic cases actually have mutations in the known familial genes, due to either de novo mutations or inheritance from an asymptomatic parent.

In severe sporadic cases with additional neurological symptoms, the frequency of identifiable genetic variants may be much higher.

Clinical Features and Symptoms

Hemiplegic migraine attacks are complex events characterized by multiple types of aura symptoms that evolve over time. Understanding the typical progression helps distinguish these attacks from other serious conditions like stroke.

Diagnostic Criteria (ICHD-3)

Required features:

At least two attacks fulfilling criteria for migraine with aura
Aura consisting of both fully reversible motor weakness AND fully reversible visual, sensory, and/or speech symptoms
Not better accounted for by another diagnosis

Additional criteria for familial type: At least one first- or second-degree relative with hemiplegic migraine attacks

Typical Attack Progression

Motor aura is the hallmark of hemiplegic migraine, but it's rarely the only type of aura present. Each attack typically includes two or more different aura types that evolve over 20-30 minutes. A key feature of hemiplegic migraine aura is that it follows an ordered, anatomically mappable progression - you can trace the symptoms across brain regions as cortical spreading depression moves through them. This is quite different from MUMS, where symptoms tend to erupt simultaneously. The typical HM sequence:

Visual Aura

Usually begins first with scintillating scotoma or visual field defects

Sensory Symptoms

Numbness and paresthesia, often starting in the hand

Motor Weakness

Unilateral weakness spreading from hand to arm to face

Speech/Language

Aphasia or speech difficulties may occur

Brainstem Symptoms

Vertigo, dysarthria, ataxia, or consciousness changes

Headache

Usually develops during or after aura symptoms

Attack Characteristics

Frequency: Mean of 3 attacks per year, but ranges from a few per lifetime to 250 per year
Duration: 41-58% of patients have auras lasting over 60 minutes; 2-8% last 24 hours or more; rarely up to 4 weeks
Triggers: Stress, bright light, intense emotions, sleep changes, exertion, mild head trauma, conventional angiography, regadenoson (cardiac stress test agent)
Laterality: May switch sides between attacks; bilateral motor signs occur in up to one-third of patients
Age pattern: Attack frequency often decreases after age 50; may evolve into typical migraine without weakness

Ordered vs Avalanche Progression

Hemiplegic migraine (ordered progression): Symptoms follow a predictable sequence as cortical spreading depression moves across brain regions. Typically: visual aura → sensory symptoms → motor weakness → speech/language problems → brainstem symptoms. Each phase lasts 5-45 minutes before transitioning to the next. A neurologist can essentially map the wave's path across the cortex based on symptom timing.

MUMS (avalanche progression): Multiple symptoms erupt simultaneously in rapid succession, like a "tsunami" or "avalanche." Numbness, weakness, speech problems, and other symptoms may all begin within 30 seconds of each other. The pattern doesn't correspond neatly to a single anatomical pathway - if someone describes everything coming on at once and you can't map it cleanly on the brain, that's a strong signal to consider MUMS over hemiplegic migraine.

Detailed Symptom Progression

Motor symptoms most often start in the hand and gradually spread up into the arm and then the face. The degree of weakness can vary from mild to severe, and the unilateral features may switch sides between or during attacks.

Visual aura typically begins first and can include scintillating scotoma, visual field defects, or other typical migraine visual symptoms.

Sensory symptoms include numbness and paresthesia, often following the same distribution as the motor weakness.

Speech and language symptoms can include aphasia or dysarthria, which may be particularly concerning and stroke-like.

Brainstem symptoms (similar to migraine with brainstem aura) may include vertigo, dysarthria, ataxia, bilateral visual or sensory symptoms, hyperacusis, tinnitus, and diminished consciousness.

Neurological Examination Findings

During Attacks

Motor findings: Unilateral weakness affecting upper more than lower limbs
Reflexes: May find Babinski sign or unilateral hyperreflexia
Sensory changes: Decreased sensation in same distribution as weakness
Speech: Possible aphasia or dysarthria
Consciousness: Can range from alert to comatose in severe cases

Between Attacks (Interictal Period)

FHM1: Majority have cerebellar findings including gaze-evoked nystagmus, dysarthria, gait or limb ataxia
FHM2: Minority have cerebellar findings
FHM3: Limited data, but may have epilepsy-related findings
Most patients: Otherwise normal neurological examination

Warning: Severe Attacks

Some patients experience severe attacks with encephalopathy, coma, seizures, fever, or prolonged weakness lasting days to months. These occur in 1-33% of patients depending on the genetic subtype and require immediate medical attention. In rare cases, severe attacks can lead to permanent brain injury or death.

Diagnosis and Evaluation

Diagnosing motor migraines requires careful clinical evaluation to distinguish between hemiplegic migraine, MUMS, and more serious conditions like stroke. The key is recognizing the characteristic features of each condition while establishing the presence of migraine-related symptoms. A thorough history and physical exam remain the most important diagnostic tools - not every patient is textbook, but fitting the pattern is more reliable than any single test.

Distinguishing Physical Exam Findings in MUMS from Hemiplegic Migraine

Critical Examination Findings

MUMS examination:

Sensory/giveaway weakness affecting at least two sites on the affected side
Sudden loss of resistance during strength testing after initially normal power
Better functional performance than predicted by formal testing
Often accompanied by proprioceptive deficits (patient doesn't fully know where their limb is in space)

Hemiplegic migraine examination:

Consistent motor weakness following neuroanatomical patterns
May have Babinski sign or hyperreflexia during attacks
Weakness corresponds to degree of functional impairment
May have associated cerebellar signs (especially FHM1)

Testing for Proprioception at the Bedside

Proprioceptive deficits are an important clue to sensory weakness in MUMS. Two practical bedside tests:

Eyes-closed arm drift: Have the patient hold both arms outstretched and close their eyes. Without visual feedback, a patient with proprioceptive dysfunction may not notice their arm slowly drifting upward. This removes the visual anchor that normally compensates for the deficit.
Finger-nose test (with nuance): Ask the patient to touch their nose with eyes closed. Difficulty completing this may reflect either true ataxia or impaired proprioception. The distinction matters - a patient who appears ataxic but has otherwise intact coordination on other tests may simply not know where their finger or nose is in space. Supplementing with formal proprioception testing (e.g., joint position sense at the toes) helps clarify.

The practical point: people with neurological deficits compensate without realizing it. Removing visual compensation (eyes closed) reveals what the proprioceptive system is actually doing on its own.

When to Suspect Each Condition

Suspect Hemiplegic Migraine When:

Episodic attacks of true unilateral weakness with other aura symptoms
Young patient with stroke-like symptoms that resolve completely
Family history of similar attacks
Gradual, anatomically ordered spread of symptoms over minutes
Associated typical migraine features
Consistent motor weakness on examination

Suspect MUMS When:

Sensory/giveaway weakness on examination
Patient reports arm weakness but exam shows arm AND leg involvement
Aura doesn't map cleanly onto a single neuroanatomical pathway
High healthcare utilization with normal imaging
Chronic migraine pattern with motor complaints
Persistent weakness between migraine attacks

Red Flags Requiring Immediate Evaluation

Sudden onset of severe symptoms (possible stroke)
Persistent neurological deficits
Fever, altered consciousness, or seizures
First episode in someone over 50
Progressive worsening rather than gradual resolution

Diagnostic Testing

Brain imaging (MRI preferred over CT) is recommended for:

First episode or atypical symptoms
Prolonged attacks or incomplete recovery
Patients without established diagnosis

Genetic testing may be helpful for:

Sporadic cases with severe symptoms
Familial cases where symptoms differ between family members
Confirming diagnosis when clinical picture is unclear
Family planning - knowing whether the condition is familial and which gene is involved has implications for relatives

Distinguishing from Stroke

Hemiplegic migraine: Gradual onset over minutes, multiple aura types, complete recovery, positive symptoms (scintillations, tingling), migrainous features

Stroke: Sudden onset, negative symptoms (numbness, weakness), may have persistent deficits, less likely to have migrainous features

Exception: Cervical artery dissection can mimic hemiplegic migraine with gradual onset and migrainous features

Imaging Findings During Attacks

Brain imaging during hemiplegic migraine attacks usually shows normal findings, but several patterns may be observed:

Possible Imaging Abnormalities During Attacks

Cortical edema and enhancement: May appear contralateral to the hemiparesis

Hyperperfusion: Seen on perfusion-weighted MRI or SPECT imaging

Hypoperfusion: May occur initially, followed by hyperperfusion

Vasodilation or vasoconstriction: Visible on angiography (avoid conventional angiography as it can trigger attacks)

Prominent cerebral veins: Transient finding on susceptibility-weighted MRI corresponding to neurologic deficits

Chronic Imaging Changes

FHM1 patients: Frequently show chronic cerebellar atrophy

Severe cases: May develop cortical hemispheric atrophy, cortical laminar necrosis, or global/regional hypometabolism on PET scanning

Important: These chronic changes are uncommon and usually only seen in patients with severe, recurrent attacks

MUMS Imaging Characteristics

Brain imaging in MUMS: Always normal, even during acute attacks

Clinical significance: The contrast between dramatic clinical symptoms and consistently normal imaging is a key diagnostic feature of MUMS

Recommendation: Brain MRI should be performed for first episodes to exclude structural causes, but repeated imaging is usually unnecessary once MUMS is diagnosed

Example Case Study: MUMS Misdiagnosed as Stroke

Patient: 62-year-old woman with history of migraine with aura in teens that resolved in her 40s

New symptoms (5 years duration): Left-sided headache with nausea and light sensitivity, followed by facial numbness spreading to arm and leg, simultaneous left arm and leg weakness, speech difficulties, eyelid drooping, and severe associated migraine symptoms

Attack pattern: Unlike typical hemiplegic migraine, pain preceded numbness and weakness, and numbness/weakness occurred simultaneously rather than sequentially

Clinical course: 27 total episodes, hospitalized 17 times for "stroke," required 2 weeks of rehabilitation each time for weakness to resolve, completely normal brain imaging

Key finding: Sensory weakness on examination rather than motor weakness

Treatment success: Once taught to self-administer injectable migraine medication (Compazine), never required hospitalization again and attacks became much milder

Hormonal Considerations and Birth Control

Both hemiplegic migraine and MUMS involve migraine with aura, which creates important considerations for hormonal contraception. It's worth noting that medical education has not fully caught up here - the blanket statement that migraine with aura is a complete contraindication to all estrogen-containing birth control is now outdated. The picture is more nuanced, and different professional organizations reflect this range of thinking.

The Contraception Controversy

The core issue: Migraine with aura is a statistically significant risk factor for vascular events (stroke, heart attack, blood clots). Adding estrogen-containing birth control, which is prothrombotic (increases clotting tendency), may compound this risk.

Why it's controversial: Different medical organizations provide conflicting recommendations, and the actual risk increase is debated among specialists. The absolute risk for any individual patient is low, but the relative risk increase is real and needs to be weighed against individual circumstances.

Professional Organization Guidelines

American College of Obstetrics and Gynecology (Most Restrictive)

All hormonal birth control options considered unsafe in migraine with aura
Recommends avoiding all estrogen-containing contraceptives
Most conservative approach - and the one most commonly (and sometimes incorrectly) taught as blanket dogma

American Academy of Neurology/American Headache Society (Moderate)

Try to limit to lowest estrogen dose possible
Avoid high-dose estrogen (≥20 micrograms ethinyl estradiol)
Contraindicated if estrogen provokes or changes aura patterns
Consider individual risk factors

International Headache Society (Most Liberal)

Depends on other individual risk factors
May allow estrogen in patients without additional risks
Most permissive approach with careful monitoring

Additional Risk Factors to Consider

Cardiovascular risks: High cholesterol, high blood pressure, diabetes
Family history: Bleeding or clotting disorders in patient or family
Smoking: Significantly increases vascular risk
Age: Risk increases after age 35
Aura changes: If estrogen provokes or alters aura patterns, that's a clear signal to stop

Safe Contraceptive Options

Generally considered safe for motor migraine patients:

Progesterone-only options: Pills, injections, implants
IUDs: Both hormonal (progesterone) and non-hormonal (copper)
Barrier methods: Condoms, diaphragms, cervical caps
Non-hormonal: Fertility awareness methods, sterilization

Key point: Progesterone is not associated with increased clotting risk - only estrogen-containing contraceptives raise concerns. Decisions should be individualized based on the patient's full vascular risk profile, not applied as a blanket rule.

Living with MUMS: A Patient Perspective

Understanding the real-world impact of MUMS helps healthcare providers and families appreciate the complexity of this condition. The following insights come from Cannon Hodge (@migrainebabe), a patient advocate living with MUMS, and highlight both challenges and coping strategies.

Symptom Patterns and Progression

Typical attack sequence: "It comes on like an avalanche or tsunami - hand goes numb, 10 seconds later speech begins to slur, 10 seconds later can't hold up head, 10 seconds after that face begins to freeze and lip tugs down. All within about 30 seconds."

Variable duration: Symptoms can last anywhere from a few minutes to several months, with three months being reported as the longest duration for some symptoms.

Persistent baseline symptoms: Many patients experience ongoing paresthesia (tingling/numbness) and weakness between attacks, particularly on the dominant side.

Comprehensive Symptom Profile

Motor Symptoms

Right-sided weakness (arm predominantly), neck weakness causing head drop, leg weakness, full-body paralysis in severe attacks

Facial Involvement

Facial paralysis, facial droop, inability to open mouth during severe attacks, dysphasia (swallowing difficulties)

Speech and Language

Dysarthria, stuttering, aphasia, complete inability to speak during severe episodes

Sensory Features

Persistent paresthesia, blurred vision, visual phenomena (fairy lights, visual snow), vertigo and dizziness

Associated Symptoms

Ataxia and clumsiness, nausea and vomiting, tinnitus, allodynia (a hallmark MUMS symptom)

Severe Episodes

Complete body paralysis except left hand, inability to sit up or support torso, episodes lasting hours to months

Key Distinguishing Features from Patient Experience

Proprioception issues:
- "When I lift my arm, it feels like someone's pushing down on it"
- "I can slowly try to coax movement from toe up, but my legs still will feel like sand"
Inconsistent patterns: "Every attack is different - rarely follows the same formula"
Allodynia prominence: Severe skin sensitivity as a consistent feature
Functional preservation: Left hand often remains functional even during severe attacks
Jazz-like variability: Symptoms change and flow unpredictably, unlike the ordered progression of hemiplegic migraine

Practical Coping Strategies

Communication Tools

Pre-written phone messages: Bulleted messages like "Can you take me to a seat," "Can you help me get on the bus," with header explaining "I'm having a migraine attack, you don't need to call an ambulance"

Point-and-communicate system: During speech difficulties, can point to needed message for others to read

Medical alert devices: Button-activated emergency communication for severe attacks with paralysis

Self-Management Techniques

Breath work: Progressive muscle relaxation and controlled breathing for maintaining control during overwhelming symptoms

Education: Learning everything possible about MUMS to reduce fear and improve understanding

Independence maintenance: Continuing to live independently and make plans despite unpredictable symptoms

Medication preparedness: Quick access to rescue medications when early symptoms appear

"Once you understand the layers of what's happening to your body, it becomes less scary. When you can't move your body, at least you can control how you breathe, and that gives you better control when everything else is spinning out of control."

Treatment and Management

Treatment for both conditions focuses on two fronts: managing acute attacks and preventing future ones. The key distinction that shapes treatment is whether the patient has hemiplegic migraine or MUMS - this isn't just a semantic difference. It directly determines whether triptans and DHE are on the table as treatment options.

A useful framing when approaching treatment: focus first on the most disabling aspect of the condition for that specific patient. For some, it's the motor symptoms. For others, especially with MUMS, the associated photophobia, nausea, or prodrome may be what's most limiting daily function. Treatment should be targeted accordingly, not just aimed at pain.

Treatment Category	Medication	Detailed Dosing & Evidence
Frequent/Prolonged Aura (First-Line)	Verapamil (sustained-release)	Dosing: Start 120 mg once daily → 120 mg twice daily → 120 mg three times daily (max 360 mg/day for most patients, 120 mg/day max for small/elderly patients) Evidence: Case series showed complete resolution in 50% within first month Why it works for HM: Verapamil directly targets the calcium channel dysfunction underlying FHM1, making it a more mechanism-based choice than most preventives Monitoring: Blood pressure, heart rate, constipation, peripheral edema Most commonly used and effective for hemiplegic migraine. Also first-line for MUMS.
Headache-Predominant (First-Line)	Flunarizine	Dosing: 2.5-5 mg once daily (evening), titrate to 10mg/day as needed Evidence: Study of 13 children showed ≥50% reduction in attack frequency in 85% Availability: Unavailable in United States Highly effective when available
Alternative Headache Treatment	Topiramate	Dosing: Start 25 mg daily, increase by 25-50 mg weekly to max 100 mg BID Rationale: Standard migraine preventive, subset of migraine with aura Good alternative when flunarizine unavailable
Alternative Headache Treatment	Amitriptyline	Dosing: Start 10 mg at bedtime, increase weekly up to 50 mg at bedtime Rationale: Standard migraine preventive with additional pain modulation Consider for comorbid depression or sleep issues
Familial Hemiplegic Migraine (First-Line)	Acetazolamide	Dosing: 250 mg twice daily Mechanism: Particularly effective for channelopathies colocalized with FHM1 Evidence: Effective in related conditions (hypokalemic periodic paralysis, episodic ataxia type 2) Side effects: Paresthesias, taste changes, kidney stones (rare) Specifically targets ion channel dysfunction - especially worth considering for confirmed FHM1
Refractory Aura-Predominant	Lamotrigine	Dosing: Start 25 mg daily, slow titration in 25 mg steps weekly/biweekly to 100 mg daily (max 300 mg studied) Evidence: Case series of 47 patients with migraine aura, including 2 with hemiplegic migraine; prospective study of 59 patients showed reduced aura intensity Critical Warning: Rash in up to 10%, Stevens-Johnson syndrome risk (~1 in 1000 adults) Contraindication: Age <16 years (dramatically increased Stevens-Johnson risk) Discontinue immediately for any rash - difficult to distinguish benign from life-threatening
Acute Aura Management	Intranasal Ketamine	Evidence: Reproducible decrease in aura intensity and duration in 5 of 11 FHM patients when given at attack onset Administration: Must be given at very early symptom onset Specialized use for acute aura interruption
Refractory Prevention	OnabotulinumtoxinA	Protocol: Injections every 12 weeks Evidence: Case series of 11 patients (4 FHM, 7 sporadic) showed reduction in frequency and severity of pain and aura Consider for patients failing first-line therapies
CGRP Inhibition (Limited Data)	Galcanezumab, Fremanezumab	Evidence: Small series of 6 patients - 4 had reduction in weakness days, 2 had increase Note: CGRP infusion failed to induce aura in FHM patients, suggesting CGRP may play a different role in HM than in typical migraine Gepants: No specific data for HM or MUMS, but gepants may show particular benefit for non-pain symptoms (photophobia, nausea) and could be explored - especially for patients where these are the most disabling features Mixed results; evidence base is limited. May work differently than in typical migraine.
Acute Supportive (Severe Attacks)	IV Naloxone	Dosing: 0.4 mg IV Evidence: Case report of aura symptom resolution within 2 minutes (did not help headache) Experimental use for severe aura symptoms

Acute Management of Severe Attacks

Patients with severe hemiplegic migraine attacks may require hospitalization due to fever, depressed consciousness, seizures, or prolonged weakness. Management includes both supportive care and specific interventions:

Supportive Management

IV hydration: Maintain adequate fluid balance
Antiemetics: Prochlorperazine 10 mg with diphenhydramine 12.5 mg pretreatment (prevents akathisia)
Magnesium sulfate: 1-2 g IV (mixed evidence but good safety profile)
IV opioids: When necessary with careful monitoring
Monitor for complications: Seizures, cerebral edema, prolonged neurological deficits

Corticosteroids for Severe Attacks

Evidence base: Limited to pediatric case reports, but may be beneficial for resistant severe symptoms

Methylprednisolone: 100 mg daily for 5 days (pediatric case report)
Dexamethasone: 0.5 mg/kg daily divided into 3 doses for 3 days, followed by gradual oral tapering
Combination therapy: Early treatment with pulse corticosteroids plus hypertonic saline showed benefit in case with CACNA1A-related encephalopathy

Experimental Severe Attack Management

Hypertonic saline (3% solution):

Dosing: 1.5 mL/kg/hour, adjusted to maintain sodium levels 145-155 mEq/L
Duration: 2 days in reported case
Indication: Cases with cerebral edema on MRI
Evidence: Single pediatric case report with sporadic HM and CACNA1A-related encephalopathy
Outcome: Reduction in seizures and attack duration

MUMS Treatment Approach

Treatment of MUMS requires aggressive migraine management rather than stroke-focused interventions. As a distinct migraine subtype, MUMS often responds well to specialized migraine therapies tailored to its unique characteristics. One of the most practically important things to establish early: MUMS patients can use triptans and DHE, which expands the acute treatment toolkit meaningfully compared to hemiplegic migraine.

MUMS Treatment Principles

Treat as migraine, not stroke: Focus on migraine preventive and acute therapies

Triptans and DHE are options: Unlike hemiplegic migraine, these are not contraindicated in MUMS

Patient education: Explain MUMS as a distinct migraine subtype to reduce anxiety and prevent unnecessary hospitalizations

Avoid repeated testing: Once diagnosed, resist the urge for repeated stroke workups

Address disability: 58% have persistent weakness requiring comprehensive care

Target the most disabling symptom: For some patients this is the motor features; for others it may be photophobia, nausea, or prodrome - treat accordingly

Quick intervention: Rapid treatment at symptom onset prevents severe progression

Injectable Medications for MUMS

Injectable formulations appear more effective for MUMS than oral medications, possibly due to absorption issues during severe attacks. Options include:

Metoclopramide (Reglan): Injectable anti-nausea medication with migraine benefits
Injectable anti-inflammatories: Non-oral NSAIDs for better absorption
Compazine (prochlorperazine): Can be self-administered by injection during attacks
Rationale: Bypass potential absorption problems and provide faster relief

MUMS Treatment Category	Recommended Options	Dosing & Special Considerations
First-Line Preventive	Verapamil (sustained-release)	240-480 mg daily. Most commonly used and effective option for MUMS
Aura-Predominant Cases	Lamotrigine	25-400 mg daily, titrated slowly. Particularly effective for severe aura symptoms
Refractory Cases	Ketamine Infusions	0.1 mg/kg/hr titrated over 3-5 days. 75% show significant improvement in specialized protocols
Acute Treatment	NSAIDs, Triptans, Ergotamines, Antiemetics, Corticosteroids	Triptans and ergotamines can be used in MUMS - this is a key practical difference from hemiplegic migraine. Intranasal ketamine may reduce aura intensity. Injectable formulations preferred during severe attacks due to absorption concerns
Alternative Options	Topiramate, Valproic Acid, Amitriptyline	Standard migraine preventive dosing. Used for patients who fail first-line therapy

Medications Generally Avoided for Hemiplegic Migraine

Triptans and Ergotamines - Complex Considerations

Traditional avoidance of triptans is based on theoretical concerns rather than robust evidence of harm:

Historical exclusion: Patients with hemiplegic migraine were excluded from original triptan clinical trials due to theoretical vasoconstriction concerns - but these trials were built on the (now outdated) vascular theory of migraine
Limited safety evidence exists: A retrospective study of 76 hemiplegic migraine patients found triptans beneficial and safe for headache phase treatment, with no ischemic strokes reported
One prolonged attack: A single patient had a prolonged hemiplegic attack persisting months after triptan use
Current practice varies: Some headache specialists now use triptans selectively for the headache phase; others maintain strict avoidance. This is an area where specialist experience and judgment matters.

Ergotamines have stronger contraindication evidence:

Case reports of serious complications: Cardiac arrest, cerebral infarcts, spinal cord infarcts
Increased ischemic risk: Netherlands case-control study showed ergotamine overuse as a risk factor for ischemic complications (OR 2.55, 95% CI 1.22-5.36)
Stroke concern: Some patients presenting with hemiplegic migraine symptoms may actually have acute ischemic stroke; vasoconstrictive medications could worsen cerebral ischemia

Critical distinction: These concerns about triptans and ergotamines apply to hemiplegic migraine only. Patients with MUMS can use triptans and DHE - this is one of the most clinically important reasons to distinguish between the two conditions.

Beta Blockers and IV Dihydropyridine Calcium Channel Blockers

Avoided by some specialists due to theoretical concerns:

Beta blocker concerns: May potentially prolong symptoms or limit compensatory cerebral vasodilatory capacity
IV dihydropyridine blockers: May lead to cerebral hypoperfusion
Case report: IV nimodipine possibly provoked seizure during prolonged FHM2 attack
Evidence limitation: These are theoretical concerns and not well-supported by clinical evidence

Detailed Treatment Monitoring and Decision-Making

Verapamil Monitoring Protocol

Titration schedule:

Week 1-2: 120 mg sustained-release once daily
Week 3-4: 120 mg twice daily (total 240 mg daily)
Week 5+: 120 mg three times daily (total 360 mg daily) if needed

Maximum dosing:

Most patients: 360 mg daily maximum
Small/elderly patients: 120 mg daily maximum

Required monitoring:

Blood pressure: Check before each dose increase
Heart rate: Monitor for bradycardia
Side effects: Constipation (most common), peripheral edema

Expected response: Some patients achieve complete resolution within the first month. In rare cases, some specialists use low-dose calcium channel blockers on an as-needed basis for infrequent but disabling attacks - typically as an early acute intervention when attacks are too infrequent to warrant daily prevention.

Lamotrigine Safety Monitoring

Critical safety protocol:

Starting dose: 25 mg daily only
Titration: Increase by 25 mg steps weekly or biweekly (slow titration is essential - rushing increases rash risk)
Target dose: 100 mg daily if needed (studied up to 300 mg daily)
Age restriction: Contraindicated under age 16 due to dramatically increased Stevens-Johnson syndrome risk

Rash monitoring:

Frequency: Up to 10% develop rash in first 1-2 months
Action required: Immediate discontinuation for ANY rash
Clinical challenge: Difficult to distinguish benign from life-threatening rash initially
Stevens-Johnson risk: ~1 in 1000 adults, much higher in children

Treatment Decision Algorithm

Choose initial therapy based on:

Frequent/prolonged aura predominant: Start verapamil
Headache pain predominant: Start flunarizine (if available), topiramate, or amitriptyline
Confirmed familial hemiplegic migraine: Consider acetazolamide first - this directly targets the underlying channelopathy
Attack frequency: Higher frequency favors daily preventive therapy
Attack severity: More severe attacks warrant more aggressive prevention
Most disabling symptom: Let this guide which class of medication you start with - if photophobia and nausea are more disabling than pain, some patients may benefit from CGRP-targeting approaches even though evidence in HM/MUMS is limited
Comorbid conditions: Choose agents that may benefit other conditions (e.g., amitriptyline for comorbid depression; topiramate for comorbid anxiety)

Prognosis and Long-term Outlook

The prognosis for hemiplegic migraine is generally favorable, but varies significantly based on genetic subtype, attack severity, and presence of complications. Understanding prognostic factors helps guide both treatment decisions and patient counseling.

Complete Recovery

Nearly all patients recover completely from individual attacks, though symptoms may be prolonged for hours to days

Age-Related Changes

Attack frequency often decreases after age 50; attacks may evolve into typical migraine without motor symptoms

Severe Complications

Permanent deficits, cognitive decline, or death occur rarely, mostly in patients with severe attacks involving coma or seizures

Prognostic Factors by Genetic Subtype

FHM1 Prognosis

Severe attacks: 33% in some studies, often with coma and prolonged hemiplegia
Cerebellar signs: Majority develop interictal cerebellar findings
S218L variant: Particularly severe - mild trauma can trigger life-threatening attacks
Recovery: Usually complete, but may take longer than other subtypes

FHM2 Prognosis

Variable phenotype: Different variants cause different patterns
Some variants: Associated with frequent, long-lasting hemiplegia
Intellectual disability: Rare, but reported with seizures in some families
Cerebellar involvement: Less common than FHM1

FHM3 Prognosis

Limited data: Only few families reported
Epilepsy risk: Higher than other subtypes
Unique features: Elicited repetitive daily blindness
Overall prognosis: Appears similar to other subtypes

Factors Associated with Better Prognosis

Positive Prognostic Indicators
Typical attack pattern without severe features (coma, seizures, fever)
Good response to preventive medications
Absence of frequent prolonged attacks (>24 hours)
No history of encephalopathy during attacks
Normal interictal neurological examination
Attacks that completely resolve without residual deficits

Risk Factors for Complications

Early onset: Patients with severe attacks beginning in childhood
Recurrent severe attacks: Multiple episodes with coma, seizures, or prolonged weakness
Specific genetic variants: Particularly CACNA1A S218L variant
Head trauma sensitivity: Patients whose attacks are triggered by minor head trauma
Incomplete recovery: Attacks that don't resolve completely between episodes

Long-term Outcomes and Complications

Rare but Serious Complications

Permanent brain injury: Reported in patients with severe, recurrent attacks

Cerebral infarction: Very rare, usually in context of extremely severe attacks

Cognitive decline: May occur with repeated severe episodes

Death: Extremely rare, associated with severe attacks with cerebral edema

Chronic cerebellar atrophy: Common in FHM1, usually not progressive

MUMS Prognosis and Long-term Outcomes

The prognosis for MUMS differs significantly from hemiplegic migraine due to its distinct characteristics as a migraine subtype, but patients face substantial ongoing challenges that require specialized care.

Persistent Symptoms

58% experience ongoing weakness between attacks, creating substantial functional impairment

Treatment Response

71% believe migraine treatment improves their weakness symptoms

Healthcare Impact

Higher emergency visits and job loss rates compared to typical migraine patients

MUMS Prognostic Factors

Better prognosis associated with:

Early recognition and appropriate migraine treatment
Patient understanding of MUMS as a migraine subtype
Episodic rather than chronic migraine pattern
Good response to preventive medications

Challenges include:

High rate of stroke misdiagnosis creating anxiety and driving unnecessary testing
Persistent interictal weakness affecting daily function
Need for long-term specialized migraine care
Employment and disability issues

Important Takeaways

Essential Points for Patients and Providers

Hemiplegic Migraine:

Rare but serious genetic condition - affects 1 in 10,000 people with known ion channel mutations
True motor weakness is the defining feature - always accompanied by other aura symptoms in an ordered, anatomically mappable sequence
Genetic testing can guide treatment - especially helpful for familial cases, severe sporadic cases, and family planning
Treatment is individualized - based on attack pattern, genetics, and which symptoms are most disabling
Triptans and DHE are traditionally avoided - though evidence is limited and specialist practice varies
Prognosis is generally good - most patients recover completely with appropriate management

MUMS (Migraine with Unilateral Motor Symptoms):

Likely more common than hemiplegic migraine - and frequently misclassified as HM due to lack of formal ICHD criteria
Sensory/giveaway weakness distinguishes it from motor weakness - the pattern on exam matters
Often misdiagnosed as stroke - despite consistently normal brain imaging
Triptans and DHE can be used - this is a critical practical difference from hemiplegic migraine
Aggressive migraine treatment works - 71% improve with proper migraine management
Persistent symptoms common - 58% have ongoing weakness between attacks
Patient education crucial - understanding MUMS as a migraine subtype reduces anxiety and unnecessary hospitalizations

When to Seek Immediate Medical Care

First episode of weakness and neurological symptoms (either condition)
Symptoms lasting longer than usual or not resolving
Fever, seizures, or altered consciousness during an attack
New or different symptoms compared to previous attacks
Sudden onset weakness (possible stroke - requires emergency evaluation)

Both hemiplegic migraine and MUMS require specialized care and ongoing monitoring. If you suspect you or a family member may have either condition, work with a neurologist or headache specialist experienced in managing complex migraine disorders. The key is accurate diagnosis to ensure appropriate treatment and avoid unnecessary testing or inappropriate stroke treatments.

The Need for Subspecialty Care

Both conditions are complex enough to require care beyond general neurology:

Primary care limitations: Most primary care physicians are not familiar with hemiplegic migraine or MUMS
General neurology gaps: Even neurologists may not be familiar with the detailed literature - MUMS isn't in the ICHD, and hemiplegic migraine is rare enough that many neurologists have never diagnosed it
Headache specialist expertise: Subspecialty headache care is often necessary for optimal diagnosis and treatment
Importance of experience: Choose providers who have diagnosed and treated these conditions before and can answer your questions with nuance

Important Disclaimer

This information is for educational purposes only and should not replace professional medical advice.

References

Ophoff RA, Terwindt GM, Vergouwe MN, et al. Familial hemiplegic migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell 1996; 87:543.
Ducros A, Denier C, Joutel A, et al. The clinical spectrum of familial hemiplegic migraine associated with mutations in a neuronal calcium channel. N Engl J Med 2001; 345:17.
De Fusco M, Marconi R, Silvestri L, et al. Haploinsufficiency of ATP1A2 encoding the Na+/K+ pump alpha2 subunit associated with familial hemiplegic migraine type 2. Nat Genet 2003; 33:192.
Dichgans M, Freilinger T, Eckstein G, et al. Mutation in the neuronal voltage-gated sodium channel SCN1A in familial hemiplegic migraine. Lancet 2005; 366:371.
Riant F, Roos C, Roubertie A, et al. Hemiplegic Migraine Associated With PRRT2 Variations: A Clinical and Genetic Study. Neurology 2022; 98:e51.
Russell MB, Ducros A. Sporadic and familial hemiplegic migraine: pathophysiological mechanisms, clinical characteristics, diagnosis, and management. Lancet Neurol 2011; 10:457.
Thomsen LL, Kirchmann M, Bjornsson A, et al. The genetic spectrum of a population-based sample of familial hemiplegic migraine. Brain 2007; 130:346.
Lykke Thomsen L, Kirchmann Eriksen M, Faerch Romer S, et al. An epidemiological survey of hemiplegic migraine. Cephalalgia 2002; 22:361.
Thomsen LL, Eriksen MK, Roemer SF, et al. A population-based study of familial hemiplegic migraine suggests revised diagnostic criteria. Brain 2002; 125:1379.
Thomsen LL, Ostergaard E, Olesen J, Russell MB. Evidence for a separate type of migraine with aura: sporadic hemiplegic migraine. Neurology 2003; 60:595.
Yu W, Horowitz SH. Treatment of sporadic hemiplegic migraine with calcium-channel blocker verapamil. Neurology 2003; 60:120.
Peer Mohamed B, Goadsby PJ, Prabhakar P. Safety and efficacy of flunarizine in childhood migraine: 11 years' experience, with emphasis on its effect in hemiplegic migraine. Dev Med Child Neurol 2012; 54:274.
Athwal BS, Lennox GG. Acetazolamide responsiveness in familial hemiplegic migraine. Ann Neurol 1996; 40:820.
Battistini S, Stenirri S, Piatti M, et al. A new CACNA1A gene mutation in acetazolamide-responsive familial hemiplegic migraine and ataxia. Neurology 1999; 53:38.
Pascual J, Caminero AB, Mateos V, et al. Preventing disturbing migraine aura with lamotrigine: an open study. Headache 2004; 44:1024.
Lampl C, Katsarava Z, Diener HC, Limmroth V. Lamotrigine reduces migraine aura and migraine attacks in patients with migraine with aura. J Neurol Neurosurg Psychiatry 2005; 76:1730.
Kaube H, Herzog J, Käufer T, et al. Aura in some patients with familial hemiplegic migraine can be stopped by intranasal ketamine. Neurology 2000; 55:139.
Chen TY, Garza I, Dodick DW, Robertson CE. The Effect of OnabotulinumtoxinA on Aura Frequency and Severity in Patients With Hemiplegic Migraine: Case Series of 11 Patients. Headache 2018; 58:973.
Artto V, Nissilä M, Wessman M, et al. Treatment of hemiplegic migraine with triptans. Eur J Neurol 2007; 14:1053.
Klapper J, Mathew N, Nett R. Triptans in the treatment of basilar migraine and migraine with prolonged aura. Headache 2001; 41:981.
Wammes-van der Heijden EA, Rahimtoola H, Leufkens HG, et al. Risk of ischemic complications related to the intensity of triptan and ergotamine use. Neurology 2006; 67:1128.
Main ML, Ramaswamy K, Andrews TC. Cardiac arrest and myocardial infarction immediately after sumatriptan injection. Ann Intern Med 1998; 128:874.
Jayamaha JE, Street MK. Fatal cerebellar infarction in a migraine sufferer whilst receiving sumatriptan. Intensive Care Med 1995; 21:82.
Olesen J. International Classification of Headache Disorders. Lancet Neurol 2018; 17:396.
Evans RW. Diagnostic Testing for Migraine and Other Primary Headaches. Neurol Clin 2019; 37:707.
Silberstein SD. Practice parameter: evidence-based guidelines for migraine headache (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000; 55:754.
Fedak EM, Zumberge NA, Heyer GL. The diagnostic role for susceptibility-weighted MRI during sporadic hemiplegic migraine. Cephalalgia 2013; 33:1258.
Hansen JM, Schytz HW, Larsen VA, et al. Hemiplegic migraine aura begins with cerebral hypoperfusion: imaging in the acute phase. Headache 2011; 51:1289.
Dreier JP, Jurkat-Rott K, Petzold GC, et al. Opening of the blood-brain barrier preceding cortical edema in a severe attack of FHM type II. Neurology 2005; 64:2145.
Kors EE, Terwindt GM, Vermeulen FL, et al. Delayed cerebral edema and fatal coma after minor head trauma: role of the CACNA1A calcium channel subunit gene and relationship with familial hemiplegic migraine. Ann Neurol 2001; 49:753.
Vanmolkot KR, Stroink H, Koenderink JB, et al. Severe episodic neurological deficits and permanent mental retardation in a child with a novel FHM2 ATP1A2 mutation. Ann Neurol 2006; 59:310.
Pelzer N, Hoogeveen ES, Ferrari MD, et al. Brain atrophy following hemiplegic migraine attacks. Cephalalgia 2018; 38:1199.
Stam AH, Louter MA, Haan J, et al. A long-term follow-up study of 18 patients with sporadic hemiplegic migraine. Cephalalgia 2011; 31:199.
Schwedt TJ, Zhou J, Dodick DW. Sporadic hemiplegic migraine with permanent neurological deficits. Headache 2014; 54:163.
Sánchez-Albisua I, Schöning M, Jurkat-Rott K, Lerche H. Possible effect of corticoids on hemiplegic attacks in severe hemiplegic migraine. Pediatr Neurol 2013; 49:286.
Young WB, Oshinsky ML, Shechter AL, et al. Migraine with unilateral motor symptoms: a case-control study. J Neurol Neurosurg Psychiatry 2007; 78:600-604.
Young WB, Peres MF, Rozen TD. MUMS the word. Migraine with unilateral motor symptoms: what can you say? J Headache Pain 2007; 8:254-258.
Bashir A, Lipton RB, Ashina S, Ashina M. Migraine and structural changes in the brain: a systematic review and meta-analysis. Neurology 2013; 81:1260-1268.
Krymchantowski AV, Jevoux C, Bigal ME. Migraine with unilateral motor symptoms: clinical and therapeutic aspects. Arq Neuropsiquiatr 2010; 68:362-365.
Burke T. Clinical perspectives on hemiplegic migraine and MUMS. Association of Migraine Disorders Podcast, 2024.
Young WB. Understanding migraine aura and motor symptoms: beyond traditional classification. Jefferson Headache Center Educational Series, 2024.
Berk T, White CS. Migraine with aura, hemiplegic migraine, and MUMS: a discussion. Neura Health, December 2024.

Migraine Phases and Timeline Migraine with Brainstem Aura

Currency